TGR5 expression in benign, preneoplastic and neoplastic lesions of Barrett’s esophagus: Case series and findings

Table 1 Clinical features of the study group

Number	34
Age (yr)
Range	48-91
Median	65.5
Sex, n (%)
Male	28 (82.4)
Female	6 (17.6)

Table 2 TGR5 expression in squamous mucosa, Barrett’s esophagus, low-grade dysplasia, high-grade dysplasia and esophageal adenocarcinoma n (%)

	Negative	Weak	Moderate	Strong
Squamous mucosa, n = 18	13 (72)	5 (28)	0	0
Barrett’s esophagus, n = 15	1 (6.7)	12 (80)	2 (13.3)	0	P < 0.001, compared with squamous mucosa
Low grade dysplasia, n = 8	0	5 (62.5)	2 (25)	1 (12.5)	P > 0.05, compared with BE
High grade dysplasia, n = 9	1 (11.1)	0	2 (22.2)	6 (66.7)	P < 0.001, compared with BE
					P < 0.05, compared with low grade dysplasia
EA, n = 16	0	0	7 (43.7)	9 (56.3)	P < 0.001, compared with BE
					P < 0.01, compared with low grade dysplasia

EA: Esophageal adenocarcinoma; BE: Barrett’s esophagus.

Table 3 TGR5 expression in different clinical stages of esophageal adenocarcinoma n (%)

Clinical stage	Negative	Weak	Moderate	Strong
I and II, n = 9	0	0	4 (44.4)	5 (55.6)
III and IV, n = 7	0	0	3 (42.9)	4 (57.1)	P > 0.05

Table 4 TGR5 expression in different pathological stages of esophageal adenocarcinoma n (%)

Pathological stage	Negative	Weak	Moderate	Strong
T1 and T2	0	0	2 (40)	3 (60)
T3 and T4	0	0	4 (36.4)	7 (63.6)	P > 0.05

Table 5 TGR5 expression in patients with or without lymph node metastasis of esophageal adenocarcinoma n (%)

Lymph node metastasis	Negative	Weak	Moderate	Strong
Positive	0	0	2 (33.3)	4 (66.7)	P > 0.05
Negative	0	0	5 (50)	5 (50)